GLP1R and cancer: Power calculations suggested that we had 80% power to detect ORs ranging from 1.40 to 2.62 (in PPARG analyses), 2.03 to 8.34 (in ABCC8 analyses) and 2.22 to 8.78 (in GLP1R analyses) per mmol/mol reduction in target-mediated inverse rank normal transformed [IRNT] HbA1c across all cancer endpoints (α=0.05).